- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02156791
Safety, Clinical Tolerability and Immunogenicity of Increasing Doses of gpASIT+TM
June 5, 2014 updated by: BioTech Tools S.A.
Safety, Clinical Tolerability and Immunogenicity of Increasing Doses of gpASIT+TM Administered Subcutaneously to Hay Fever Patients
gpASIT+TM product is based on highly purified allergen fragments obtained from grass pollen.
The purpose of this clinical trial is to confirm the safety, clinical tolerability and immunogenicity of increasing doses of gpASIT+TM administered subcutaneously to patients with grass pollen-induced allergic rhinoconjunctivitis, and to determine the maximal tolerated dose of gpASIT+TM .
Study Overview
Study Type
Interventional
Enrollment (Actual)
61
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Dresden, Germany, 01307
- Universitätsklinikum Carl-Gustav-Carus, Dresden, Germany
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Signed and dated Informed Consent Form by a legally competent patient
- Female or male patients aged 18-70 years
- The patients are in good physical and mental health according to his/her medical history and vital signs
- Non-pregnant, non-lactating females with adequate contraception
- Females unable to bear children must have signed the form for adequate contraceptive protection (i.e. tubule ligation, hysterectomy, or post-menopausal (defined as a minimum of one year since the last menstrual period))
Allergy diagnosis:
- A medical history of moderate to severe seasonal allergic rhinoconjunctivitis (SAR) for the grass pollen season during at least the two previous years
- A positive skin prick test (wheal diameter ≥ 3 mm) to grass-pollen mixture, histamine wheal ≥ 3 mm, NaCl control reaction ≤ 2 mm
- Specific IgE against grass pollen (IgE > 0.7 kU/l)
- Patients treated with anti-allergic medication for at least 2 years prior to enrolment
In asthmatic patients:
- Confirmed diagnosis of controlled asthma according to GINA-guidelines (GINA 2011)
Exclusion Criteria:
- Simultaneous participation in other clinical trials or previous participation within 30 days before inclusion
- Previous immunotherapy with grass allergens within the last 5 years
- Ongoing immunotherapy
- Patients being in any relationship or dependence with the Sponsor and/ or Investigator
- Inability to understand instructions/ study documents
- Patients with a history of hypersensitivity to the excipients of investigational products
- Patients with partly controlled or uncontrolled asthma
- Chronic asthma or emphysema, particularly with a FEV 1 <80% of the predicted value (ECSC)
- Patients symptomatic to perennial inhalant allergens to which the subjects are regularly exposed
- Patients with a history of ragweed allergy
- Patients with a history of renal disease or chronic hepatic disease
- Patients with malignant disease
- Patients with a know severe autoimmune disease and patients with a positive test to ANA, ANCA or ASCA
- Patients with any chronic disease which may impair the patient's ability to participate in the trial (i.e. severe congestive heart failure, active gastric ulcer, inflammatory bowel disease, uncontrolled diabetes mellitus, etc…)
- Patients requiring beta-blockers/ACE-inhibitors medication
- Patients requiring anti-IgE antibodies, mast cell stabilizers, and antileukotriene agents
- Patients with any contraindication for the use of adrenaline
- Patients with febrile illness (> 37.5°C, oral)
- Patients with a known positive serology for HIV-1/2, HBV or HCV
- Patients who are immunocompromised by medication or illness, have received a vaccine corticoids or immunosuppressive medications within 1 month before trial entry
- Female patients who are pregnant, lactating, or of child-bearing potential and not protected from pregnancy by a sufficiently reliable method
- Consumption of corticoids (oral, topic or nasal) or of anti-histaminic drugs within 3 weeks preceding the trial (screening visit)
- Patients with laboratory values greater than grade 1 according to the FDA Guidance for Industry for preventive Vaccine Trials (FDA 2007)
- Unreliable patients including non-compliant patients, patients with known alcoholism or drug abuse or with a history of a serious psychiatric disorder as well as patients unwilling to give informed consent or to abide by the requirements of the protocol
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: gpASIT+TM
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
(Serious) adverse events
Time Frame: Up to 6 weeks
|
Up to 6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Grass pollen allergen -specific immunoglobulins
Time Frame: up to 6 weeks
|
up to 6 weeks
|
Blocking antibody production
Time Frame: up to 6 weeks
|
up to 6 weeks
|
Change from baseline in Conjunctival Provocation Test score
Time Frame: at screening, after 4 weeks and 6 weeks of treatment
|
at screening, after 4 weeks and 6 weeks of treatment
|
Local reaction at the injection site
Time Frame: up to 6 weeks
|
up to 6 weeks
|
Systemic reaction after injection
Time Frame: up to 6 weeks
|
up to 6 weeks
|
Change from baseline in safety laboratory parameters
Time Frame: up to 6 weeks
|
up to 6 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Bettina Hauswald, MD, Universitätsklinikum Carl-Gustav-Carus, Dresden, Germany
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2013
Primary Completion (Actual)
December 1, 2013
Study Completion (Actual)
December 1, 2013
Study Registration Dates
First Submitted
May 23, 2014
First Submitted That Met QC Criteria
June 2, 2014
First Posted (Estimate)
June 5, 2014
Study Record Updates
Last Update Posted (Estimate)
June 6, 2014
Last Update Submitted That Met QC Criteria
June 5, 2014
Last Verified
May 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BTT-gpASIT007
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hay Fever
-
BioTech Tools S.A.Completed
-
Pascoe Pharmazeutische Praeparate GmbHCompleted
-
BioTech Tools S.A.Completed
-
Centre Hospitalier Universitaire VaudoisCompleted
-
ASIT Biotech S.A.Unknown
-
AstraZenecaCompletedRhinitis, Allergic, Seasonal | Hay FeverCanada
-
AstraZenecaCompletedRhinitis, Allergic, Seasonal | Hay FeverCanada
-
AstraZenecaCompletedRhinitis, Allergic, Seasonal | Hay FeverCanada
-
AstraZenecaCompletedRhinitis, Allergic, Seasonal | Hay FeverUnited States
-
BioTech Tools S.A.CompletedHay Fever | Grass Pollen AllergyBelgium, France, Luxembourg
Clinical Trials on gpASIT+TM
-
BioTech Tools S.A.Completed
-
BioTech Tools S.A.CompletedSeasonal Allergic RhinoconjunctivitisBelgium
-
BioTech Tools S.A.CompletedHay Fever | Grass Pollen AllergyBelgium, France, Luxembourg
-
BioTech Tools S.A.CompletedSeasonal Allergic RhinoconjunctivitisBelgium
-
BioTech Tools S.A.CompletedSeasonal Allergic RhinoconjunctivitisBelgium
-
ASIT Biotech S.A.Unknown
-
BioTech Tools S.A.Completed
-
Washington University School of MedicineNational Cancer Institute (NCI); National Institutes of Health (NIH); Atrium...CompletedVentral Hernia | AdhesionsUnited States
-
NephroSantNot yet recruitingKidney Transplant Failure and Rejection
-
University Hospital TuebingenTerminatedApnea of Prematurity | Continuous Positive Airway Pressure | CPAP